
    
      2. Clinical hypothesis

        1. SGLT2 inhibitor ameliorates fatty liver and obesity.

        2. SGLT2 inhibitor stimulates sympathetic activity.

        3. SGLT2 inhibitor increases glucagon secretion.

        4. SGLT2 inhibitor enhances lipolysis and hepatic glucose production.
    
  